Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2010

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

  28677-2927
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of September 7, 2010, the registrant had outstanding 2,573,100 shares of Common Stock.

 

 

 


Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JULY 31, 2010

 

          Page Number

PART I. FINANCIAL INFORMATION

  

Item 1

   Financial Statements   
   Consolidated Statements of Operations – Three months ended July 31, 2010 and 2009    1
   Consolidated Balance Sheets – July 31, 2010 and April 30, 2010    2
   Consolidated Statements of Cash Flows – Three months ended July 31, 2010 and 2009    3
   Notes to Consolidated Financial Statements    4

Item 2

   Management’s Discussion and Analysis of Financial Condition and Results of Operations    6
   Review by Independent Registered Public Accounting Firm    8
   Report of Independent Registered Public Accounting Firm    9

Item 3

   Quantitative and Qualitative Disclosures About Market Risk    10

Item 4

   Controls and Procedures    10

PART II. OTHER INFORMATION

  

Item 6

   Exhibits    11

SIGNATURE

   12

 

i


Table of Contents

Part 1. Financial Information

 

Item 1. Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

     Three months ended
July  31,
 
     2010     2009  

Net sales

   $ 24,858      $ 26,249   

Costs of products sold

     19,859        20,485   
                

Gross profit

     4,999        5,764   

Operating expenses

     3,901        3,966   
                

Operating earnings

     1,098        1,798   

Interest expense

     (45     (41
                

Earnings before income taxes

     1,053        1,757   

Income tax expense

     329        589   
                

Net earnings

     724        1,168   

Less: net earnings attributable to the noncontrolling interest

     (67     (97
                

Net earnings attributable to Kewaunee Scientific Corporation

   $ 657      $ 1,071   
                

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

    

Basic

   $ 0.26      $ 0.42   

Diluted

   $ 0.25      $ 0.42   

Weighted average number of common shares outstanding (in thousands)

    

Basic

     2,573        2,556   

Diluted

     2,578        2,558   

See accompanying notes to consolidated financial statements.

 

1


Table of Contents

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

     July 31,
2010
    April 30,
2010
 
     (Unaudited)        

Assets

    

Current Assets:

    

Cash and cash equivalents

   $ 1,812      $ 1,722   

Restricted cash

     521        544   

Receivables, less allowance

     27,425        26,169   

Inventories

     8,226        8,350   

Deferred income taxes

     392        390   

Prepaid expenses and other current assets

     1,369        1,407   
                

Total Current Assets

     39,745        38,582   

Property, plant and equipment, at cost

     45,352        43,200   

Accumulated depreciation

     (29,947     (29,385
                

Net Property, Plant and Equipment

     15,405        13,815   

Deferred income taxes

     690        663   

Other

     3,540        3,561   
                

Total Other Assets

     4,230        4,224   
                

Total Assets

   $ 59,380      $ 56,621   
                

Liabilities and Stockholders’ Equity

    

Current Liabilities:

    

Short-term borrowings

   $ 7,496      $ 4,872   

Current obligations under capital leases

     78        82   

Accounts payable

     9,046        9,540   

Employee compensation and amounts withheld

     1,514        1,358   

Deferred revenue

     714        586   

Other accrued expenses

     1,956        2,059   
                

Total Current Liabilities

     20,804        18,497   

Obligations under capital leases

     99        119   

Accrued employee benefit plan costs

     6,464        6,333   
                

Total Liabilities

     27,367        24,949   

Equity:

    

Common stock

     6,550        6,550   

Additional paid-in-capital

     890        855   

Retained earnings

     28,798        28,398   

Accumulated other comprehensive loss

     (5,025     (4,898

Common stock in treasury, at cost

     (473     (472
                

Total Kewaunee Scientific Corporation Stockholders’ Equity

     30,740        30,433   

Noncontrolling interest

     1,273        1,239   
                

Total Equity

     32,013        31,672   
                

Total Liabilities and Equity

   $ 59,380      $ 56,621   
                

See accompanying notes to consolidated financial statements.

 

2


Table of Contents

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

     Three months ended
July  31,
 
     2010     2009  

Cash flows from operating activities:

    

Net earnings

   $ 724      $ 1,168   

Adjustments to reconcile net earnings to net cash (used in) provided by operating activities:

    

Depreciation

     589        615   

Bad debt provision

     43        36   

Provision for deferred income tax expense

     (29     17   

Decrease in prepaid income taxes

     —          9   

(Increase) decrease in receivables

     (1,299     616   

Decrease (increase) in inventories

     124        (1,509

(Decrease) increase in accounts payable and other accrued expenses

     (441     651   

Increase (decrease) in deferred revenue

     128        (339

Other, net

     73        (18
                

Net cash (used in) provided by operating activities

     (88     1,246   

Cash flows from investing activities:

    

Capital expenditures

     (2,179     (2,011

Decrease (increase) in restricted cash

     23        (11
                

Net cash used in investing activities

     (2,156     (2,022

Cash flows from financing activities:

    

Dividends paid

     (257     (205

Increase in short-term borrowings

     2,624        509   

Payments on capital leases

     (24     (81

Purchase of Treasury Stock

     (36     —     

Proceeds from exercise of stock options (including tax benefit)

     35        —     
                

Net cash provided by financing activities

     2,342        223   

Effect of exchange rate changes on cash

     (8     38   
                

Increase (decrease) in cash and cash equivalents

     90        (515

Cash and cash equivalents, beginning of period

     1,722        3,559   
                

Cash and cash equivalents, end of period

   $ 1,812      $ 3,044   
                

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2010 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Inventories

Inventories consisted of the following (in thousands):

 

     July 31, 2010    April 30, 2010

Finished products

   $ 1,825    $ 2,199

Work in process

     1,374      1,237

Raw materials

     5,027      4,914
             
   $ 8,226    $ 8,350
             

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

C. Comprehensive Income

A reconciliation of net earnings and total comprehensive income for the three months ended July 31, 2010 and 2009 is as follows (in thousands):

 

     Three months ended
July 31, 2010
    Three months ended
July 31, 2009

Net earnings

   $ 657      $ 1,071

Change in cumulative foreign currency translation adjustments

     (116     104

Change in fair value of cash flow hedge, net of tax

     (11     —  
              

Total comprehensive income

   $ 530      $ 1,175
              

Assets and liabilities for the Company’s foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in stockholders’ equity.

 

4


Table of Contents

D. Segment Information

The following table provides financial information by business segments for the three months ended July 31, 2010 and 2009 (in thousands):

 

     Domestic
Operations
   International
Operations
   Corporate     Total

Three months ended July 31, 2010

          

Revenues from external customers

   $ 20,948    $ 3,910    $ —        $ 24,858

Intersegment revenues

     663      644      (1,307     —  

Operating earnings (loss) before income taxes

     1,585      228      (760     1,053

Three months ended July 31, 2009

          

Revenues from external customers

   $ 23,358    $ 2,891    $ —        $ 26,249

Intersegment revenues

     420      107      (527     —  

Operating earnings (loss) before income taxes

     2,545      303      (1,091     1,757

E. Defined Benefit Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. No contributions were paid to the plans during the three months ended July 31, 2010 and 2009. The Company calculated that contributions in the amount of $719,000 were required for fiscal year 2011, and the Company paid these contributions in August 2010.

Pension expense (income) consisted of the following (in thousands):

 

     Three months ended
July 31, 2010
    Three months ended
July 31, 2009
 

Service cost

   $ -0-      $ -0-   

Interest cost

     240        230   

Expected return on plan assets

     (289     (235

Recognition of net loss

     172        160   
                

Net periodic pension expense

   $ 123      $ 155   
                

F. Derivative Instruments and Hedging Activities

Cash Flow Hedges – Interest Rate Swap Agreement

As described in Note G below, in June 2010, the Company entered into an interest rate swap agreement with a initial notional amount of $4 million, whereby the interest rate payable by the Company on the unpaid balance of the new term loan is effectively converted to a fixed interest rate of 4.875% for the period beginning August 2, 2010, and ending August 1, 2017. The Company entered into this interest rate swap to mitigate future interest rate risk associated with advances under the credit facility. The Company does not use derivatives for trading or speculative purposes. The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (loss) and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. The Company did not record any hedge ineffectiveness in earnings during the three months ended July 31, 2010 and 2009. Amounts reported in accumulated other comprehensive loss related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s revolving credit facility.

The change in fair value of cash flow hedges, net of tax for the three months ended July 31, 2010 was $11,000. The change in fair value was recorded in the Company’s consolidated balance sheet as a current liability and accumulated other comprehensive loss.

 

5


Table of Contents

G. Subsequent Events

On August 2, 2010, the Company amended its existing bank agreement covering its unsecured $14 million revolving credit facility to provide for an additional $4 million seven-year term loan secured by the Company’s real property and equipment located in Statesville, North Carolina. The term loan requires monthly principal payments of approximately $17,000, plus interest calculated at the 30-day LIBOR Market Index Rate plus 1.575%, with payment of the outstanding principal balance and any unpaid interest at the term loan maturity date. In June 2010, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on the term loan was effectively converted to a fixed interest rate of 4.875%, effective August 2, 2010. The term loan includes financial covenants similar to the unsecured revolving credit facility. The proceeds of the term loan will be used primarily to fund the expansion of the Company’s Statesville, North Carolina manufacturing facilities.

H. Reclassifications

Certain 2009 amounts have been reclassified to conform with the 2010 presentation in the consolidated statements of cash flows. Such reclassifications had no impact on net earnings.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2010 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2010. The following discussion and analysis describes material changes in the Company’s consolidated financial condition since April 30, 2010. The analysis of results of operations compares the three months ended July 31, 2010 with the comparable period of the prior fiscal year.

Results of Operations

Sales for the three months ended July 31, 2010 were $24,858,000, a decrease of 5% from sales of $26,249,000 in the same period last year. Sales from Domestic Operations were $20,948,000, a decrease of 10% from the prior year period. The decline was primarily the result of on-going softness in the marketplace for small and mid-sized laboratory projects and the scheduled timing of shipments in the order backlog. Sales from International Operations were $3,910,000, an increase of 35% from the prior year period, as the Company experienced increased international sales opportunities.

The gross profit margin for the three months ended July 31, 2010 was 20.1% of sales, as compared to 22.0% of sales in the comparable quarter of the prior year. The decreases in the gross profit margin percentages were primarily due to lower sales prices due to the competitive marketplace.

Operating expenses for the three months ended July 31, 2010 were $3,901,000, or 15.7% of sales, as compared to $3,966,000, or 15.1% of sales, in the comparable period of the prior year. The decrease in expenses was primarily due to lower incentive compensation expense, partially offset by higher operating expenses at our foreign subsidiaries. The increase in expense as a percent of sales was due to the lower sales level in the current year period.

Operating earnings were $1,098,000 for the three months ended July 31, 2010. This compares to operating earnings of $1,798,000 for the comparable period of the prior year.

Interest expense was $45,000 for the three months ended July 31, 2010, as compared to $41,000 for the comparable period of the prior year. The increase for the current year period resulted from an increase in short-term borrowings.

 

6


Table of Contents

Income tax expense of $329,000 was recorded for the three months ended July 31, 2010, as compared to income tax expense of $589,000 recorded for the comparable period of the prior year. The effective tax rate was 31.2% for the three months ended July 31, 2010, and was 33.5% for the comparable period of the prior year. The effective tax rates for each of the current year and prior year period were below the statutory tax rates due to the combination of lower income tax rates in the geographic locations of the Company’s subsidiaries and the impact of state and federal income tax credits on domestic operations income.

Noncontrolling interests related to the Company’s two subsidiaries that are not 100% owned by the Company reduced net earnings by $67,000 for the three months ended July 31, 2010, as compared to a reduction of $97,000 for the comparable period of the prior year. The decrease in minority interests in the current year period was directly related to lower earnings of the Company’s two subsidiaries in the current year.

Net earnings were $657,000, or $0.25 per diluted share, for the three months ended July 31, 2010. This compares to net earnings of $1,071,000, or $0.42 per diluted share, for the comparable period of the prior year.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Certain machinery and equipment are financed by non-cancellable operating leases or capital leases. Additionally, the current expansion of the Company’s Statesville, North Carolina manufacturing facilities is to be funded by a new $4 million term loan. See Note G of the Notes to the Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report Form 10-Q for a description of the term loan agreement and related interest rate swap. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $18.9 million at July 31, 2010, compared to $20.1 million at April 30, 2010. The ratio of current assets to current liabilities was 1.9-to-1.0 at July 31, 2010, compared to 2.1-to-1.0 at April 30, 2010. At July 31, 2010, advances of $7,496,000 were outstanding under the Company’s bank revolving credit facility, as compared to advances of $4,872,000 outstanding as of April 30, 2010.

The Company’s operations used cash of $88,000 during the three months ended July 31, 2010. Cash was provided from operating earnings and offset by an increase of $1,299,000 in accounts receivable. The Company’s operations provided cash of $1,246,000 during the three months ended July 31, 2009 as cash provided from earnings and a decrease of $616,000 in accounts receivable, which were partially offset by cash used to fund an increase in inventory on hand.

During the three months ended July 31, 2010, net cash of $2,156,000 was used in investing activities, primarily for capital expenditures. This compares to the use of $2,022,000 for investing activities in the comparable period of the prior year, primarily for capital expenditures.

The Company’s financing activities provided cash of $2,342,000 during the three months ended July 31, 2010. Cash provided included $2,624,000 received from short-term borrowings, which was partially offset by cash dividends of $257,000 paid to stockholders. Financing activities provided cash of $223,000 during the three months ended July 31, 2009. Cash provided included $509,000 received from short-term borrowings, which was partially offset by cash dividends paid of $205,000 and payments on obligations under capital leases of $81,000.

Outlook for Fiscal Year 2011

The Company’s ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company’s role as subcontractor or supplier to dealers for subcontractors, and the fact that demand for its products is dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction.

The Company expects that sales and earnings for the first half of fiscal year 2011 will likely be below the prior year period, followed by a stronger second half of the year. The Company’s expectations are based on a number of factors, including scheduled delivery dates for orders in the order backlog, a partial recovery of the global economy, continuing increased sales opportunities for the Company’s products in the international marketplace, sales and earnings benefits from new products, and increased manufacturing capabilities in the Company’s Statesville, North Carolina and Bangalore, India facilities.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking. Over time, the Company’s actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company’s forward-looking statements, and such difference might be significant and harmful to stockholders’ interests. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of the Company’s 2010 Annual Report on Form 10-K.

 

7


Table of Contents

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three month periods ended July 31, 2010 and July 31, 2009 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company’s independent registered public accounting firm. Their report on the interim consolidated financial information follows.

 

8


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of July 31, 2010, and the related consolidated statements of operations for the three month periods ended July 31, 2010 and 2009 and the related consolidated statements of cash flows for the three-month periods ended July 31, 2010 and 2009. These interim consolidated financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2010 and the related consolidated statements of operations, of stockholder’s equity and of cash flows for the year then ended (not presented herein) and in our report dated July 16, 2010, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2010 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

 

/s/ Cherry, Bekaert & Holland, L.L.P.
Charlotte, North Carolina
September 13, 2010

 

9


Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2010.

 

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2010. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of July 31, 2010, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

10


Table of Contents

PART II. OTHER INFORMATION

 

Item 6. Exhibits

 

10.1    Kewaunee Scientific Corporation Fiscal Year 2011 Incentive Bonus Plan.*(1)
31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

* The referenced exhibit is a management contract or compensatory plan, or arrangement.
(1) Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0–5286) filed on June 28, 2010, and incorporated herein by reference.

 

11


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

KEWAUNEE SCIENTIFIC CORPORATION

(Registrant)

Date: September 14, 2010     By  

/s/ D. Michael Parker

      D. Michael Parker
      (As duly authorized officer and Senior Vice President, Finance and Chief Financial Officer)

 

12